» Articles » PMID: 24133598

Clinicopathological Features of Acute Promyelocytic Leukemia: an Experience in One Institute Emphasizing the Morphological and Immunophenotypic Changes at the Time of Relapse

Overview
Specialty Pathology
Date 2013 Oct 18
PMID 24133598
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Acute promyelocytic leukemia (APL) has two morphological variants, namely macrogranular (M3) and microgranular (M3v). M3v, characterized by the presence of neoplastic promyelocytes with only sparse fine azurophilic granules, accounts for 10-25% of all APL and has unique biological characteristics. Relapse occurs in approximately 20% of patients with APL. The morphological type of the leukemic cells at relapse is usually identical with the primary disease, and only one case of morphological change at relapse has been reported. Here, we analyzed the clinicopathological features of APL, including 4 relapsed cases emphasizing morphological changes at the time of relapse. The unique finding of the present study is that 2 of 4 relapsed cases changed from M3 to M3v at relapse. The morphological features of these were different in each case (one had blastic features and the other resembled monocytoid leukemic cells). Cytogenetic analyses revealed the continued presence of t(15;17)(q22;q12) at the time of relapse and morphological change. Moreover, the immune phenotype of the leukemic cells changed from CD2(-)/CD34(-) to CD2(+)/CD34(+) at that time. These findings suggest that morphological change at relapse in APL may not be a rare event, and that the leukemic cells can show variable morphological features at the time of relapse, which could result in misdiagnosis as a different type of acute myeloid leukemia. Therefore, a comprehensive approach with emphasis on combined morphological, immunophenotypic, and cytogenetic analyses is important for diagnosis and appropriate treatment of relapsed APL.

Citing Articles

Spinal myeloid sarcoma presenting as initial symptom in acute promyelocytic leukemia with a rare cryptic fusion gene: a case report and literature review.

Zhang X, Wang T, Chen P, Chen Y, Wang Z, Xu T Front Oncol. 2024; 14:1375737.

PMID: 38835381 PMC: 11148225. DOI: 10.3389/fonc.2024.1375737.


Cytoreductive chemotherapy in induction therapy plays a key role in the prognosis of patients with low-risk acute promyelocytic leukaemia.

Zhu X, Tang F, Yu W, Zhao X, Qin Y, Jiang Q J Cell Mol Med. 2024; 28(10):e18252.

PMID: 38766688 PMC: 11103457. DOI: 10.1111/jcmm.18252.


Acute promyelocytic leukemia in a long-standing HIV-positive patient: Case report and literature review.

Mendes-de-Almeida D, de Souza Fernandez T, Lamim Lovatel V, da Rocha M, Gomes B, Monte-Mor B Leuk Res Rep. 2022; 18:100339.

PMID: 35958242 PMC: 9361310. DOI: 10.1016/j.lrr.2022.100339.


[Application of immunophenotypic analysis and molecular genetics in the diagnosis of acute promyelocytic leukemia].

Gong J, Li Y, Li C, Wang Y, Liu Y, Wang C Zhonghua Xue Ye Xue Za Zhi. 2019; 40(4):288-293.

PMID: 31104439 PMC: 7343010. DOI: 10.3760/cma.j.issn.0253-2727.2019.04.005.


Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai, China.

Liu M, Weng X, Gong S, Chen H, Ding J, Guo M Oncotarget. 2017; 8(46):80625-80637.

PMID: 29113330 PMC: 5655225. DOI: 10.18632/oncotarget.20814.


References
1.
Dimov N, Medeiros L, Ravandi F, Bueso-Ramos C . Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features. Am J Clin Pathol. 2010; 133(3):484-90. DOI: 10.1309/AJCPJ7K0AWMBHMAI. View

2.
Sanz M, Coco F, Martin G, Avvisati G, Rayon C, Barbui T . Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000; 96(4):1247-53. View

3.
Foley R, Soamboonsrup P, Carter R, Benger A, Meyer R, Walker I . CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol. 2001; 67(1):34-41. DOI: 10.1002/ajh.1073. View

4.
Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Hyodo H . Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood. 2010; 116(26):6018-22. DOI: 10.1182/blood-2010-06-289389. View

5.
Paietta E, Goloubeva O, Neuberg D, Bennett J, Gallagher R, Racevskis J . A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom. 2004; 59(1):1-9. DOI: 10.1002/cyto.b.20001. View